# Retatrutide FAQ: Trials, Dosing, Mechanism, Availability and Regulatory Status > Retatrutide FAQ: plain, cited answers on the trials, mechanism, doses studied, half-life, FDA status and availability of this investigational triple agonist. The questions readers ask most, answered plainly from the trial and regulatory record — investigational status kept in plain view. ## How does retatrutide compare to a dual GLP-1/GIP agonist in Phase 3 studies? A 2025 meta-analysis of three randomized trials (878 patients) put retatrutide's mean weight difference at -14.33% versus placebo [13], and mechanistically it adds a glucagon receptor arm a dual agonist lacks [3]. A direct head-to-head Phase 3 trial against a dual GIP/GLP-1 agonist is underway but has not yet reported. ## What cardiovascular and kidney outcomes is retatrutide being evaluated for in Phase 3? Dedicated cardiovascular- and kidney-outcome trials are part of the Phase 3 program (NCT06383390 [17]; TRANSCEND-CKD [23]). Incretin reviews describe renoprotective signals in type 2 diabetes and obesity [9], while class mechanistic work notes cAMP-mediated cardiac contractile effects that long-term outcome data are still needed to characterize [10]. ## What did the Phase 2 trial find about retatrutide dose escalation from 2 mg to 12 mg? The 48-week Phase 2 obesity trial used stepwise escalation across 1, 4, 8, and 12 mg once weekly. The 12 mg arm reached a mean -24.2% body-weight change versus -2.1% with placebo, with dose-related gastrointestinal adverse events that the escalation schedule was designed to manage [1]. ## What does retatrutide do? Retatrutide is a single-molecule triple agonist that activates the GLP-1, GIP, and glucagon receptors at once [3]. A 2025 review synthesizes its Phase 1/2 data, characterizing the up-to ~24% weight loss at 12 mg over 48 weeks as a step-change versus prior incretin therapies [6]. ## How does retatrutide work? Cryo-EM structures show retatrutide engaging the GLP-1, GIP, and glucagon receptors as one peptide [3]. The GLP-1/GIP arms suppress appetite and improve glucose-dependent insulin secretion, while controlled glucagon activation adds energy expenditure and hepatic fat handling [6]. ## How to reconstitute retatrutide? There is no approved formulation, storage, or reconstitution standard for retatrutide — it has been studied only as a controlled clinical-trial investigational product given by once-weekly subcutaneous injection. This is research context, not preparation instructions. ## Is retatrutide FDA approved? No. As of 2026 retatrutide is investigational, in Phase 3 clinical trials (Eli Lilly), and not approved by the FDA or any other regulator. Its efficacy and safety figures come from trials, not approved labeling [1][6]. ## When will retatrutide be available? There is no approved product. Availability depends on completion of the ongoing Phase 3 TRIUMPH program (NCT05929066 [20], among others) and subsequent regulatory review, which has not occurred as of 2026. On retatrutide availability, access has been limited to clinical trials. ## How to take retatrutide? In trials, retatrutide was given as a once-weekly subcutaneous injection with stepwise dose escalation [1][4]. It is investigational with no approved dosing; this describes trial administration, not a recommendation to use it. ## How long does retatrutide take to work? Trial data describe reduced appetite and progressive weight loss over weeks of once-weekly dosing, with the largest Phase 2 body-weight changes accruing across the 36–48 week treatment periods [1][2]. ## Is retatrutide better than tirzepatide? No controlled head-to-head trial has been published; a dedicated active-comparator Phase 3 study is underway [7]. Across separate trials, retatrutide's triple-agonist Phase 2 weight-loss figures are numerically large [1], but cross-trial comparison is not a substitute for a direct trial. ## How much retatrutide per week? Trials studied once-weekly subcutaneous doses from roughly 0.5 mg up to 12 mg with escalation [1][4]. This is the studied research range, not a recommended human dose; retatrutide is investigational and unapproved. ## How to mix retatrutide with bacteriostatic water? No approved preparation standard exists; retatrutide was supplied as a controlled clinical-trial product. Gray-market research-labeled material is unregulated and of unverified identity, purity, and sterility. This is regulatory context, not mixing instructions. ## How to switch from tirzepatide to retatrutide? There is no established clinical protocol for switching between these agents outside a trial; retatrutide is investigational and unapproved, and a head-to-head study is still ongoing [7]. ## Is retatrutide a GLP-3? No. The informal 'GLP-3' label is not an official pharmacological class. Retatrutide is accurately described as a GIP/GLP-1/glucagon receptor triple agonist — a 'GGG' tri-agonist — confirmed by cryo-EM structural work [3]. ## Is retatrutide available? Not as an approved product. Access has been limited to clinical trials; there is no lawful prescription or consumer product for retatrutide as of 2026. ## What is retatrutide used for? In trials it has been studied for obesity and type 2 diabetes [1][2], with additional Phase 2 investigation in metabolic dysfunction-associated steatotic liver disease [5] and in weight-linked comorbidities such as obstructive sleep apnea and knee osteoarthritis [14], plus ongoing cardiovascular and kidney-outcome studies [17]. ## What receptors does retatrutide target? Three class-B G-protein-coupled receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor, engaged by a single acylated peptide as confirmed by cryo-EM structural studies [3]. ## Is retatrutide legal? Retatrutide is an unapproved investigational drug; it is not authorized for sale or human use outside a clinical trial. Gray-market research-labeled material sits outside any regulatory oversight. ## How often do you take retatrutide? Trials used once-weekly subcutaneous administration, supported by an approximately six-day elimination half-life measured in the first-in-human Phase 1b study [4]. ## What is the half-life of retatrutide? The first-in-human Phase 1b trial reported an approximately six-day half-life, which supports once-weekly subcutaneous dosing [4]. ## How to store retatrutide? No approved storage standard exists; retatrutide has only been handled as a controlled clinical-trial investigational product. This is regulatory context, not storage instructions. --- An illuminated reading of the retatrutide trial record — Phase 1b pharmacokinetics through the Phase 3 TRIUMPH program, each figure lettered back to its source, and no clinic, prescription, or apothecary behind the page.